BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9932102)

  • 21. Basement membrane pathology: a feature of acute equine laminitis.
    Pollitt CC
    Equine Vet J; 1996 Jan; 28(1):38-46. PubMed ID: 8565952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equine laminitis model: lamellar histopathology seven days after induction with oligofructose.
    Van Eps AW; Pollitt CC
    Equine Vet J; 2009 Nov; 41(8):735-40. PubMed ID: 20095219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo priming and ex vivo activation of equine neutrophils in black walnut extract-induced equine laminitis is not attenuated by systemic lidocaine administration.
    Loftus JP; Williams JM; Belknap JK; Black SJ
    Vet Immunol Immunopathol; 2010 Nov; 138(1-2):60-9. PubMed ID: 20667603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.
    Zervos EE; Shafii AE; Haq M; Rosemurgy AS
    J Surg Res; 1999 Jun; 84(2):162-7. PubMed ID: 10357914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equine laminitis: cryotherapy reduces the severity of the acute lesion.
    van Eps AW; Pollitt CC
    Equine Vet J; 2004 Apr; 36(3):255-60. PubMed ID: 15147134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The timeline of metalloprotease events during oligofructose induced equine laminitis development.
    Visser MB; Pollitt CC
    Equine Vet J; 2012 Jan; 44(1):88-93. PubMed ID: 21696433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased expression of p63, a regulator of epidermal stem cells, in the chronic laminitic equine hoof.
    Carter RA; Engiles JB; Megee SO; Senoo M; Galantino-Homer HL
    Equine Vet J; 2011 Sep; 43(5):543-51. PubMed ID: 21496086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
    Zervos EE; Shafii AE; Rosemurgy AS
    J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equine laminitis: ultrastructural lesions detected in ponies following hyperinsulinaemia.
    Nourian AR; Asplin KE; McGowan CM; Sillence MN; Pollitt CC
    Equine Vet J; 2009 Sep; 41(7):671-7. PubMed ID: 19927586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble factor(s) released from neutrophils activates endothelial cell matrix metalloproteinase-2.
    Schwartz JD; Monea S; Marcus SG; Patel S; Eng K; Galloway AC; Mignatti P; Shamamian P
    J Surg Res; 1998 Apr; 76(1):79-85. PubMed ID: 9695744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for vascular and enzymatic events in the pathophysiology of acute laminitis: which pathway is responsible for initiation of this process in horses?
    Moore RM; Eades SC; Stokes AM
    Equine Vet J; 2004 Apr; 36(3):204-9. PubMed ID: 15147125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrastructural examination of basement membrane pathology in horses with insulin-induced laminitis.
    de Laat MA; Pollitt CC
    Domest Anim Endocrinol; 2019 Oct; 69():30-34. PubMed ID: 31280023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equine laminitis: cleavage of laminin 5 associated with basement membrane dysadhesion.
    French KR; Pollitt CC
    Equine Vet J; 2004 Apr; 36(3):242-7. PubMed ID: 15147132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hoof wall wound repair.
    Pollitt CC; Daradka M
    Equine Vet J; 2004 Apr; 36(3):210-5. PubMed ID: 15147126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentration Dependent Influence of Lipopolysaccharides on Separation of Hoof Explants and Supernatant Lactic Acid Concentration in an Ex Vivo/In Vitro Laminitis Model.
    Reisinger N; Schaumberger S; Nagl V; Hessenberger S; Schatzmayr G
    PLoS One; 2015; 10(11):e0143754. PubMed ID: 26599864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinase-2 and -9 are activated in joint diseases.
    Clegg PD; Carter SD
    Equine Vet J; 1999 Jul; 31(4):324-30. PubMed ID: 10454092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokeratins of the stratum medium and stratum internum of the equine hoof wall in acute laminitis.
    Wattle O
    Acta Vet Scand; 2000; 41(4):363-79. PubMed ID: 11234970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraosseous infusion of the distal phalanx compared to systemic intravenous infusion for marimastat delivery to equine lamellar tissue.
    Underwood C; Collins SN; van Eps AW; Mills PC; Allavena RE; Bailey SR; Medina Torres CE; Meizler A; Pollitt CC
    Vet J; 2015 Sep; 205(3):357-63. PubMed ID: 26073286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
    Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
    Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.